A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

Inclusion Criteria

• •Confirmed diagnosis of AML, previously untreated, ineligible for intensive induction regimen due to age or co-morbidities.
• •Participants who are \>= 75 years of age or who are \>= 18 to 74 years of age with at least one of the following co-morbidities:
• •* Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3.
• •* Cardiac history of congestive heart failure requiring treatment or ejection fraction \<= 50% or chronic stable angina.
• •* Diffusion capacity of lung for carbon monoxide (DLCO) \<= 65% or forced expiratory volume during the first second (FEV1) \<= 65%.
• •* Adequate renal and hepatic criteria as described in the protocol.
• •* Other co-morbidities that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the AbbVie Therapeutic Area Medical Director (TA MD) before study enrollment.